The activity of the quinolone temafloxacin against respiratory pathogens was compared with those of ciprofloxacin and ofloxacin. MICs for 90% of strains tested indicated that temafloxacin was at least two-to fourfold more potent than the other two quinolones against Staphylococcus aureus, Streptococcus pneumoniae, and Legionella pneumophila. Temafloxacin had potency equal to that of ciprofloxacin and was twofold more active than ofloxacin against Streptococcus pyogenes, Moraxella catarrhalis, and Bordetella pertussis. Against Haemophilus influenzae and Klebsiella pneumoniae, temafloxacin was four-and twofold less potent than ciprofloxacin, respectively. When administered orally in mouse protection tests against S. aureus, S. pneumoniae, and S. pyogenes, temafloxacin was at least eight times more potent than ciprofloxacin and was two to four times more active than ofloxacin. Against H. influenzae, temafloxacin was as active as ofloxacin and was two times less active than ciprofloxacin following oral administration in mice. In treating L. pneumophila in guinea pigs and H. influenzae otitis media in gerbils, temafloxacin and ofloxacin were more effective than ciprofloxacin. Against S. pneumoniae otitis media in gerbils, temafloxacin and ciprofloxacin were more active than ofloxacin. Following subcutaneous administration in mice, temafloxacin achieved higher lung levels than ciprofloxacin or ofloxacin did.
subcutaneously against S. pneumoniae and Streptococcus pyogenes (13) . The improved in vivo activity seen in this study appeared to be due, in part, to the improved pharmacokinetics of temafloxacin following oral and parenteral administration. These findings suggest that temafloxacin may be effective in treating lower respiratory tract infections, including those caused by S. pneumoniae.
In the present study we characterized, in vitro and in mouse protection tests, the activity of temafloxacin against bacteria frequently associated with respiratory tract infections. In addition, temafloxacin was evaluated against experimental legionellosis and otitis media caused by S.
pneumoniae and H. influenzae. In all tests the efficacy of temafloxacin was compared with those of ciprofloxacin and ofloxacin.
MATERIALS AND METHODS
Bacterial strains. The bacteria used in this study were clinical isolates, strains from the Abbott Laboratories culture collection, or strains from the American Type Culture Collection, Rockville, Md. All bacteria were identified by standard procedures at Abbott Laboratories and were maintained frozen at -60°C.
Antimicrobial agents. Temafloxacin, ciprofloxacin, ofloxacin, and erythromycin were synthesized at Abbott Laboratories. Ampicillin was purchased from Parke-Davis (Morris Plains, N.J.). Stock solutions of quinolones for in vitro susceptibility testing were prepared in water. Other antibacterial agents were prepared according to the instructions of the manufacturer. For animal testing, all compounds were prepared in sterile injectable water.
Susceptibility testing. MICs were determined by the standard twofold dilution method in agar with 1 x 104 CFU per spot as the inoculum or by the broth microdilution method with 5 x 105 CFU per ml as the inoculum (16 (11) . Immediately prior to treatment, middle ear aspirates from four gerbils were obtained as described below and cultured to determine the level of infection at the start of therapy. Antibacterial agents were administered orally by gavage in a 0.5-ml volume beginning 17 h p.i. and continuing twice daily for two days to groups of four gerbils each. Eighteen hours after the final treatment, gerbils were killed and middle ear aspirates were collected and cultured. To obtain samples from the middle ears for culture, gerbils were killed with T-61 Euthanasia Solution and 0.02 ml of BHIB was injected into the middle ear bulla through the tympanic membrane. Middle ear aspirates were collected before removing the needle. The aspirates were diluted in BHIB and plated in duplicate onto chocolate agar (BBL) or Trypticase soy agar with 5% sheep blood for H. influenzae-or S. pneumoniae-infected gerbils, respectively. Bacterial counts were expressed as the number of CFU per middle ear. The minimum number of bacteria detectable by this method was 20 CFU per middle ear. A one-way (fixed effects) analysis of variance was used to compare the logarithms of the CFU values in treated and untreated gerbils.
Pharmacokinetics in mice and guinea pigs. The concentrations of temafloxacin, ciprofloxacin, and ofloxacin in sera and lungs were determined in female CF-1 mice (weight, 20 to 25 g). Mice were administered a single subcutaneous injection of 25 mg of antibiotic per kg of body weight. Serum samples were collected from pools of serum from five mice each at 0.5, 1, 2, 3, 6 , and 24 h after dosing. Lungs were removed from exsanguinated mice, weighed, and homogenized in 5 ml of phosphate-buffered saline. The antibiotic concentrations in sera and lungs were determined by a disk agar diffusion bioassay procedure, with K. pneumoniae ATCC 10031 used as the assay organism and seed agar medium 1 (BBL) used as the growth medium (7). The concentrations of temafloxacin, ciprofloxacin, and ofloxacin in serum also were determined in guinea pigs following a single intraperitoneal injection of 7.5 mg/kg. This dose was selected because it was the highest amount received by L. pneumophila-infected guinea pigs in efficacy studies. Groups of two guinea pigs each were bled intracardially at 0.5, 1, 2, 3, and 6 h after dosing. Levels of temafloxacin, ciprofloxacin, and ofloxacin were determined from serum samples by the microbiological assay method described above.
RESULTS
In vitro activity. The in vitro potency of temafloxacin was compared with those of ciprofloxacin and ofloxacin. The TEMAFLOXACIN AGAINST RESPIRATORY PATHOGENS Time-kill studies. The effects of temafloxacin (MIC, 0.5 ,ug/ml), ciprofloxacin (MIC, 0.5 jg/ml), and ofloxacin (MIC, 0.5 jig/ml) over time on the viability of S. pyogenes C203 were determined (Table 2 ). At 0.5 jig/ml, temafloxacin reduced bacterial counts by 1.4 log CFU, while ciprofloxacin decreased counts by 0.8 log CFU after 6 h of incubation.
Ofloxacin at 0.5 jig/ml did not reduce bacterial counts. At 1.0 ,ug/ml, a 2.4-, 1.7-, and 1.0-log-unit decrease in viable counts was seen with temafloxacin, ciprofloxacin, and ofloxacin, respectively, after 6 h. In cultures exposed to 2 jig of temafloxacin per ml, a 2.1-and 3.2-log-unit reduction in CFU was seen at 6 and 24 h, respectively. This compared with a 1.6-and 2.6-log-unit reduction in CFU in cultures exposed to 2 jig of ciprofloxacin per ml for 6 and 24 h, respectively, and a 1.8-and 2.8-log-unit reduction in CFU in cultures containing the same concentration of ofloxacin after 6 and 24 h, respectively. At 4 ,ug/ml, temafloxacin and ofloxacin both reduced the viable counts by approximately 2.0 log CFU after 6 h and by over 3 log CFU after 24 h. At all the concentrations tested, temafloxacin demonstrated the most rapid killing kinetics, reducing bacterial counts to a greater extent than equal levels of ciprofloxacin or ofloxacin did within the first 2 h of exposure.
Killing of S. pneumoniae ATCC 6303 by temafloxacin (MIC, 0.25 jig/ml), ciprofloxacin (MIC, 1.0 jig/ml), and ofloxacin (MIC, 0.5 jig/ml) was also concentration and time dependent (Table 3 ). At 0.5 jig/ml, the maximum reduction in CFU (approximately 1 log unit) was observed at 6 h for temafloxacin and ciprofloxacin, while ofloxacin did not inhibit growth. A 0.7-log-unit reduction in CFU was observed by 6 h with ofloxacin at 1 ,ug/ml, while cultures exposed to ciprofloxacin were reduced 1.3 and 2.2 log CFU by 4 and 6 h, respectively. Temafloxacin at 1 p,g/ml reduced cell counts by an additional 0.5 log CFU over that observed with ciprofloxacin. Cultures exposed to ciprofloxacin and ofloxacin at 2 ,g/ml were reduced by approximately 2 and 3 log CFU at 4 and 6 h, respectively, while cultures exposed to temafloxacin were reduced an additional 1 log CFU at these times. At 4 igIml, the bactericidal activities of these compounds were generally similar. Mouse protection tests. The results of mouse protection tests are presented in Fig. 1 and 2 . When administered orally against S. aureus, S. pneumoniae, and S. pyogenes, temafloxacin was at least eight times more potent than ciprofloxacin and two to four times more active than ofloxacin. When injected subcutaneously against these bacteria, temafloxacin Table 5 . Oral treatment with temafloxacin, ciprofloxacin, or ofloxacin at doses of as low as 10 mg/kg/day reduced bacterial counts by 5.82 to 6.10 log CFU. At 2 mg/kg/day, temafloxacin reduced bacterial counts by 3.05 log CFU, as compared with a 4.27 log CFU reduction in ofloxacin-treated gerbils. Ciprofloxacin did not lower bacterial counts at this dose. All three quinolones were more active in this model than ampicillin was, which was effective only at 50 mg/kg/day. S. pneumoniae otitis media in gerbils. Bacterial counts from the middle ear fluid of treated and untreated S. pneumoniaeinfected gerbils are given in Table 6 . At oral doses of 10 mg/kg/day, temafloxacin lowered bacterial counts to essentially undetectable levels in three of four animals. Ciprofloxacin at this dose reduced bacterial counts by 2.67 log CFU, but it did not clear the infection in any animals. Ofloxacin at 10 mg/kg/day was not effective. Ampicillin was the most Table 7 . Temafloxacin and ofloxacin achieved higher concentrations in serum and had longer serum half-lives than did ciprofloxacin. Peak lung concentrations occurred 0.5 h after injection and were higher for temafloxacin and ofloxacin. From 1 to 3 h after antibiotic administration the lung levels of temafloxacin were 1.7 to 2.0 times higher than those of the other quinolones.
Pharmacokinetics in guinea pigs. The concentrations of temafloxacin, ciprofloxacin, and ofloxacin in serum were determined after a single intraperitoneal administration of 7.5 mg/kg in guinea pigs. All three quinolones reached maximum levels in the serum within 0.5 h after injection. Temafloxacin achieved a peak level in serum of 4.0 ,ug/ml and had a serum half-life of 1.0 h. Ofloxacin had a peak level in serum of 4.3 ,ug/ml and a serum half-life of 0.9 h. The peak concentration of ciprofloxacin in serum was 1.5 ,ug/ml, and the serum half-life was 1.3 h.
DISCUSSION
The three fluoroquinolones evaluated in this study had potent activities against gram-negative respiratory pathogens. The MIC90s of temafloxacin against M. catarrhalis, H. influenzae, B. pertussis, and K. pneumoniae ranged from 0.03 to 0.12 ,ug/ml. The MIC90s of ofloxacin against the same bacteria also ranged from 0.03 to 0.12 jig/ml, while the MIC90s of ciprofloxacin were 0.008 to 0.06 ,ug/ml. These results are in agreement with the findings of numerous other studies (2, 4, 13, 18, 19) . Because of their excellent in vitro activities and pharmacokinetics, these quinolones are able to achieve peak concentrations in the serum and bronchial (6, 9, 10, 14, 15, 20, 21) . Few data exist concerning the use of quinolones in treating human legionellosis, and the potential value of these antibiotics for this indication may ultimately depend on pharmacological properties such as tissue distribution and intracellular penetration into alveolar macrophages.
The three quinolones evaluated in the present study were less active against gram-positive respiratory pathogens. Temafloxacin was the most potent against staphylococci and streptococci, with MIC90s of 0.12 to 1 ,ug/ml. The MIC%0s of ciprofloxacin and ofloxacin against these bacteria were 0.25 to 2.0 ,ug/ml. Against S. pneumoniae the MIC90 of temafloxacin was 0.25 ,ug/ml, while the MIC90s of ciprofloxacin and ofloxacin were 2.0 Vig/ml. In patients with pneumococcal infection, it is unlikely that orally administered ciprofloxacin or ofloxacin would be able to achieve levels greatly exceeding these MICs for extended periods of time (24) . Temafloxacin, because of its favorable pharmacokinetic profile in humans and fourfold greater potency against S. pneumoniae, would be more likely to achieve levels in serum and tissue greater than the MIC. Following a single subcutaneous dose of 25 mg/kg in mice, the concentrations of temafloxacin in the serum and lungs exceeded the MIC90 against S. pneumoniae (0.5 jig/ml) for 3 h. Levels of ciprofloxacin exceeded the MIC90 (2 ,ug/ml) for only 0.5 h in sera and 1 h in the lungs. Ofloxacin achieved concentrations higher than the MIC%0 (2.0 ,ug/ml) for 2 h in sera and 1 h in the lungs. Thus, therapeutic concentrations of temafloxacin were present in the lungs of mice 2 h longer than they were in mice treated with ciprofloxacin or ofloxacin. Against S. aureus, S. pneumoniae, and S. pyogenes infected in mice, temafloxacin was 2 to 11 times more potent than ciprofloxacin and 2 to 4 times more potent than ofloxacin. Temafloxacin was also more effective than ciprofloxacin and ofloxacin in treating S. pneumoniae otitis media in gerbils. Bedos et al. (3) reported that the antipneumococcal activity of temafloxacin is equal to or greater than that of erythromycin and comparable to that of amoxicillin in a mouse pneumonia model. The in vitro and in vivo potencies of temafloxacin, along with its greater lung penetration in mice, suggests that this antibacterial agent may be useful in treating lower respiratory tract infections caused by gram-positive bacteria.
